Updated on 1 April 2013
Takeda Oncology and the Worldwide Innovative Network (WIN) consortium form partnership to advance personalized cancer treatments
Singapore: Takeda Oncology and the Worldwide Innovative Network (WIN) in personalized cancer medicine consortium have formed a new partnership focused on bringing the latest advances in personalized cancer treatments to patients.
WIN is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide. It was founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone.
Mr Jesus Gomez Navarro, VP, clinical research, Millennium, a company acquired by Takeda Pharmaceutical, and a delegate to the WIN consortium, said that, "Millennium has a long-standing commitment to advancing personalized medicine in oncology.
WIN's global network of cancer centers and industry partners provides Millennium with unique opportunities to build successful industry-leading partnerships that accelerate the development of new therapies and advance our aspiration to cure cancer."
Mr John Mendelsohn, director, Khalifa Institute for Personalized Cancer Therapy and former president, MD Anderson Cancer Center, University of Texas, and chairman, WIN consortium, said that, "WIN's achievements are built by the collaborative efforts of its members. Millennium's focus on partnership development and the development of novel oncology therapeutics for a global population strongly align with WIN's mission and goals. This partnership increases the potential of the Consortium and will enhance its future achievements. We are thrilled that Millennium has become a premier member of WIN."